Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daridorexant Hydrochloride

FDA-approved product (tablet, oral), marketed as Quviviq.

Registered studies
2
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Daridorexant Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Orexin receptor antagonists
FDA pharmacologic class
Orexin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Daridorexant Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daridorexant Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Department of Defense PTSD Adaptive Platform Trial - Master Protocol

    NCT05422612 · start 2023-11-02

    Registered record
    Registry ID
    NCT05422612
    Conditions
    Post Traumatic Stress Disorder
    Interventions
    Intervention A Fluoxetine Hydrochloride (HCl); Intervention A Placebo; Intervention B Vilazodone Hydrochloride (HCl); Intervention B Placebo; Intervention C Daridorexant; Intervention C Placebo; Intervention D SLS-002; Intervention D Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2023-11-02
    Completion
    2029-07
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Traumatic Stress Disorder
    InterventionIntervention A Fluoxetine Hydrochloride (HCl); Intervention A Placebo; Intervention B Vilazodone Hydrochloride (HCl); Intervention B Placebo +4 more
    PhasePhase 2
    Registry statusSuspended

  • A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

    NCT02571855 · start 2015-10-01

    Registered record
    Registry ID
    NCT02571855
    Conditions
    Healthy Subjects
    Interventions
    ACT-541468 (hydrochloride salt); ACT-541468 (free base); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10-01
    Completion
    2016-02-01
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionACT-541468 (hydrochloride salt); ACT-541468 (free base); Placebo
    PhasePhase 1
    Registry statusCompleted